Generic Utilization, Formulary Compliance Get Boost From e-Prescribing Incentives In Some Part D Plans, OIG Finds
This article was originally published in The Pink Sheet Daily
Medicare Part D plan sponsors that track the results of their electronic prescribing initiatives report a positive influence on prescribing behavior, but many don't measure outcomes.
You may also be interested in...
While Medicare will start providing financial incentives to physicians to use e-prescribing starting in 2009, some private plans are already paying physicians and pharmacies to adopt the technology
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.